The increased level of apolipoprotein C III (APO CIII) in patients with CKD inhibits the activity of lipoprotein lipase in hydrolyzing triglycerides transported within very low-density lipoprotein (VLDL) particles and chylomicrons [6]. Here, APOC3 is linked to chronic kidney disease.